Robert Stott

PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting. “A [2015] ASGE survey reported that 78% of endoscopists had an extremity repetitive use injury, or ERI,” Daryl Ramai, MD, MPH, MSc, an advanced endoscopy

PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here. “Elafibranor — a peroxisome proliferator-activated receptor agonist — has demonstrated significant biochemical response in 51% vs. 4% of

PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here. “[Zymfentra] is a subcutaneous form of infliximab, which has shown superior efficacy over placebo for maintenance therapy up to 1 year in patients

PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.“Pancreatic focal lesions, either cystic or solid, are commonly found in imaging exams,” Miguel Mascarenhas, MD, PhD, from the University

PHILADELPHIA — None of the top 25 insurers in the United States offer explicit policy coverage for primary or revisional endoscopic bariatric therapies, according to data presented at the ACG Annual Scientific Meeting.“While lifestyle interventions have yielded transient and modest effect sizes, surgical interventions [for obesity] have produced the largest effects; however, surgeries

The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee. Although ursodeoxycholic acid (UDCA) remains the only first-line treatment for PBC, the number of patients who fail to adequately respond with UDCA or cannot tolerate its use has

Healio will present its seventh annual Disruptive Innovators Awards for gastroenterology and hepatology this fall. Individuals who have changed the face of the specialty and pushed the status quo toward betterment of the field will be recognized during a prestigious awards ceremony at the ACG Annual Meeting, scheduled for October 25-30 in Philadelphia.

Jun 17, 2024 ... In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted that the first step in building an LGBTQ-friendly gastroenterology ...

WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported. “The study was prompted by my interest in the use of anti-obesity medications in the treatment of MASLD,” Jennifer A. Panganiban, MD,

WASHINGTON — Oral antibiotic use among adult patients was not associated with increased risk for early-onset colorectal cancer, according to data presented at Digestive Disease Week. “The incidence of early-onset colorectal cancer is increasing over the past 3 decades; however, little is known about what may be driving this increase in early-onset CRC,” Jeffrey K. Lee, MD, MPH,